Granisetron plus dexamethasone may increase arrhythmia risk

Share this content:

the ONA take:

According to two studies published online ahead of print in the journal BMC Medicine, researchers have found that granisetron, a serotonin 5HT3 receptor antagonist, plus dexamethasone may increase a patient's risk for developing an arrhythmia.

Most arrhythmias are no serious; however, some put patients at a higher risk for stroke, heart failure, or cardiac arrest.

Serotonin receptor antagonists, such as granisetron, ondansetron, and palonosetron, are commony used to reduce nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, as well as in those undergoing surgery.

Results of the studies showed that the safest serotonin receptor antagonists in combination with a steroid with respect to arrhythmia were ondansetron plus dexamethasone, and dolasetron for patients of all ages.

The studies were conducted in patients undergoing anesthesia for surgery.

DNA origami can deliver targeted cancer drugs
Granisetron plus dexamethasone may increase a patient's risk for developing an arrhythmia.
Two studies published online today in BMC Medicine suggest granisetron used in combination with dexamethasone are effective in preventing nausea or vomiting (or both) in patients following surgery. But this combination could also increase patients' arrhythmia risk, the research revealed.
READ FULL ARTICLE From Medical Express
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs